Skip to search formSkip to main contentSkip to account menu

Allosteric Bcr-Abl Tyrosine Kinase Inhibitor ABL001

Known as: ABL001 
An orally bioavailable, allosteric Bcr-Abl tyrosine kinase inhibitor with potential antineoplastic activity. Designed to overcome resistance, ABL001… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer
Notch signaling has been identified as a critical pathway in gastric cancer (GC) progression and metastasis, and inhibition of… 
2019
2019
Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointestinal (GI) cancer.
3023 Background: Antiangiogenic therapy has been a successful clinical strategy for the treatment of various cancer types. To… 
2018
2018
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro
Asciminib (previously ABL001), which binds the myristate-binding pocket of the Bcr-Abl kinase domain, is in phase I clinical… 
2018
2018
First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells
Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the… 
Review
2017
Review
2017
Second line small molecule therapy options for treating chronic myeloid leukemia
ABSTRACT Introduction: Approximately 33% of chronic myeloid leukemia (CML) patients discontinue treatment with imatinib in the… 
2016
2016
Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy
Background: ABL001 is a potent, specific BCR-ABL inhibitor in development for the treatment of patients with CML and Ph+ ALL… 
2016
2016
Combining the Allosteric ABL1 Tyrosine Kinase Inhibitor ABL001 with ATP-Competitive Inhibitors to Suppress Resistance in Chronic Myeloid Leukemia
The successful design and application of ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia (CML) has… 
2015
2015
ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy
Background: ABL001 is a potent, specific BCR-ABL inhibitor in development for the treatment of patients with chronic myelogenous… 
2014
2014
ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia
Background: Chronic myelogenous leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL) are caused by the t(9;22)(q34… 
2011
2011
Pharmacological Characterization of LY593093, an M1 Muscarinic Acetylcholine Receptor-Selective Partial Orthosteric Agonist
Alzheimer's disease and schizophrenia are characterized by expression of psychotic, affective, and cognitive symptoms. Currently… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)